SINTX Technologies (SINT) restores Nasdaq listing compliance with $4.83M equity
Rhea-AI Filing Summary
SINTX Technologies, Inc. reports that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity for continued listing. Based on SINTX’s Form 10-Q for the quarter ended June 30, 2026, Nasdaq’s Listing Qualifications Staff noted stockholders’ equity of $4,830,000 (approximately $4.83 million) and confirmed that the prior deficiency matter is now closed.
The company states that it remains focused on commercializing its silicon nitride-based medical products, expanding its distribution network, and developing strategic partnerships to support future revenue growth, while working to maintain compliance with Nasdaq’s continued listing requirements.
Positive
- Nasdaq compliance restored: Nasdaq’s Listing Qualifications Staff confirmed SINTX now meets the $2.5 million minimum stockholders’ equity requirement, closing the previously reported deficiency matter.
- Improved equity position: Stockholders’ equity of $4,830,000 as of June 30, 2026 provides a buffer above the Nasdaq minimum and supports continued listing on the Nasdaq Capital Market.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Nasdaq Listing Rule 5550(b)(1) regulatory
stockholders’ equity financial
continued listing regulatory
Listing Qualifications Staff regulatory
silicon nitride biomaterials technical
FAQ
What did SINTX (SINT) disclose about its Nasdaq listing status?
What is the minimum stockholders’ equity Nasdaq requires for SINTX (SINT)?
How much stockholders’ equity did SINTX (SINT) report as of June 30, 2026?
Why was SINTX (SINT) previously non-compliant with Nasdaq’s rules?
What is the significance of Nasdaq’s August 12, 2026 letter to SINTX (SINT)?
What strategic focus did SINTX (SINT) highlight after regaining Nasdaq compliance?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s): | Name of each exchange on which registered: | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD. Disclosure.
On August 13, 2026, SINTX Technologies, Inc. (the “Company”) issued a press release announcing that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 7.01 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On August 12, 2026, the Company, received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1).
As previously disclosed in the Company’s Current Report on Form 8-K filed on May 27, 2026, on May 22, 2026, the Company received a letter from the Staff notifying it that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity for continued listing.
In the Letter, the Staff stated that, based on the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, which reported stockholders’ equity of $4,830,000 as of that date, the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), and that the matter is now closed.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release, dated August 13, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SINTX Technologies, Inc. | ||||
| Date: | August 13, 2026 | By: | /s/ Eric K. Olson | |
| Eric K. Olson | ||||
| Chief Executive Officer | ||||
Exhibit 99.1
 |
 |
SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement
SALT LAKE CITY, Utah – August 13, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders’ equity of $2.5 million.
Based on SINTX’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately $4.83 million, Nasdaq determined that the Company complies with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1) and confirmed that the previously disclosed deficiency matter is now closed.
“We are pleased to have resolved this matter and to have Nasdaq confirm our compliance with the minimum stockholders’ equity requirement,” said Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies. “This is an important step as we continue to strengthen the Company and focus our resources on the commercialization of our silicon nitride technologies and the execution of our growth strategy.”
The Company remains focused on advancing the commercialization of its silicon nitride-based medical products, expanding its distribution network and developing strategic partnerships designed to support future revenue growth.
About SINTX
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SINAPTIC Foot & Ankle Implant System for reconstructive surgery.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s commercialization initiatives, expansion of its distribution network, development of strategic partnerships, growth strategy, future revenue growth and ability to maintain compliance with the continued listing requirements of The Nasdaq Stock Market. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those described in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, except as required by applicable law.
SINTX Contacts:
Investor Relations
Gregg Honigblum, Chief Investment Officer
P: 801-839-3502
E: IR@sintx.com